Market Overview

OHR Pharmaceuticals Selling Off As Feuerstein Calls Phase II A Failure

Share:
Related
18 Biggest Mid-Day Losers For Tuesday
The Market In 5 Minutes

Shares of OHR Pharmaceuticals (NASDAQ: OHRP) are tumbling after Adam Feuerstein laid out the failure of the company’s phase II study.

As Feuerstein explained, the report looks positive; the title even totes “positive” results. This left many investors wondering why shares were selling off out of the open.

The fifth paragraph is the important one, which shows that OHR’s treatment did not outperform the placebo on the main focus of the study.

In addition, the so-called positive results are not statistically significant, Feuerstein points out.

Related: MKM Says Pandora Could Be Worth $115/Share In 5 Years

Shares of OHR Pharmaceuticals started selling off sharply when Feuerstein’s article was published, and are still dropping. The stock is at $9.87, over a 13 percent drop from Monday's close.

Latest Ratings for OHRP

DateFirmActionFromTo
Oct 2016H.C. WainwrightInitiates Coverage OnBuy
Oct 2016Brean CapitalAssumesHold
Aug 2016Brean CapitalDowngradesBuyHold

View More Analyst Ratings for OHRP
View the Latest Analyst Ratings

Posted-In: Adam FeuersteinAnalyst Color CNBC Analyst Ratings Media

 

Related Articles (OHRP)

View Comments and Join the Discussion!